Safety of Romiplostim (Nplate®) Following UCBT

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

April 10, 2015

Primary Completion Date

December 12, 2020

Study Completion Date

June 1, 2021

Conditions
Hematologic Malignancies
Interventions
DRUG

Romiplostim

Romiplostim at the assigned dose will be administered subcutaneously (SQ) once a week for 6 weeks. The dose will be assigned at the time of subject registration. This is a dose escalation to determine the maximum tolerated dose. The doses include 4 mcg/kg/dose, 6 mcg/kg/dose, 8 mcg/kg/dose, and 10 mcg/kg/dose.

Trial Locations (1)

55455

University of Minnesota Masonic Cancer Center, Minneapolis

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT02046291 - Safety of Romiplostim (Nplate®) Following UCBT | Biotech Hunter | Biotech Hunter